Antibodies directed at eIF5A1 (rabbit monoclonal (EP526Y): ab32443) and eIF5A2 (mouse monoclonal (1E7): H00056648-M01) were purchased from AbCam and Abnova, respectively. Anti-Src and phospho-Src (Tyr416) antibodies were from Cell Signaling Technology. Anti-GAPDH antibody was from Abcam, anti-survivin antibody was from Biolegend, anti-tubulin, DHPS and DOHH antibodies were from Sigma, anti-KRas antibody was from Santa Cruz Biotechnology (sc-30) and anti-PEAK1 antibody was from Millipore. The antibody specifically recognizing hypusinated eIF5A1 (NIH353) was a kind gift from Dr. Myung-Hee Park (NIH), which has been validated for use in western blotting [35 (link)] and immunohistochemistry [5 (link), 36 (link)] in human as well as mouse tissues and cell lines. GC7 (N1-guanyl-1, 7-diaminoheptane) was purchased from Calbiochem, CPX (ciclopirox olamine) was from Santa Cruz Biotechnology. Cisplatin was purchased from Enzo Life Sciences, and gemcitabine was from Eli Lilly and used as described previously [30 (link)]. Human pancreatic cancer tissue arrays were purchased from US Biomax (PA2081a except for DOHH staining, where PA803 was used).